These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 22920745)

  • 1. Breathlessness, night sweats, and weight loss on natalizumab.
    Dahdaleh D; Altmann DM; Malik O; Nicholas RS
    Lancet; 2012 Aug; 380(9843):726-7. PubMed ID: 22920745
    [No Abstract]   [Full Text] [Related]  

  • 2. Tuberculosis in London: not unexpected.
    Anderson C; Hopkins S; Adeboyeku D; Maguire H
    Lancet; 2013 Jan; 381(9862):201. PubMed ID: 23332956
    [No Abstract]   [Full Text] [Related]  

  • 3. Tuberculosis in London: not unexpected - Authors' reply.
    Nicholas R; Dahdaleh D; Altmann DM; Malik O
    Lancet; 2013 Jan; 381(9862):201-2. PubMed ID: 23332955
    [No Abstract]   [Full Text] [Related]  

  • 4. Asymptomatic lung disease caused by Mycobacterium kansasii as an opportunistic infection in a patient treated with natalizumab for relapsing-remitting multiple sclerosis.
    Hradilek P; Zeman D; Tudik I; Zapletalova O; Ulmann V
    Mult Scler; 2014 Apr; 20(5):639-40. PubMed ID: 23959714
    [No Abstract]   [Full Text] [Related]  

  • 5. Severe anemia in a patient with multiple sclerosis treated with natalizumab.
    Simone AM; Ferraro D; Vitetta F; Marasca R; Bonacorsi G; Pinelli G; Federzoni L; Nichelli PF; Sola P
    Neurology; 2014 Jul; 83(4):374-5. PubMed ID: 24944259
    [No Abstract]   [Full Text] [Related]  

  • 6. Severe anemia in a patient with multiple sclerosis treated with natalizumab.
    Seibert JB; Alvarez E
    Neurology; 2015 Feb; 84(8):861. PubMed ID: 25713115
    [No Abstract]   [Full Text] [Related]  

  • 7. Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?
    Maillart E; Louapre C; Lubetzki C; Papeix C
    Mult Scler; 2014 Apr; 20(4):505-9. PubMed ID: 24367037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe haematological complications during treatment with natalizumab.
    Midaglia L; Rodriguez Ruiz M; Muñoz-García D
    Mult Scler; 2012 Nov; 18(11):1644-6. PubMed ID: 22438058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effectiveness and safety of natalizumab in multiple sclerosis: data of the first five years from the TOP (Tysabri Observational Program)].
    Magdolna S
    Ideggyogy Sz; 2014 May; 67(5-6):211-2. PubMed ID: 25087382
    [No Abstract]   [Full Text] [Related]  

  • 10. Natalizumab-induced autoimmune hepatitis in a patient with multiple sclerosis.
    Martínez-Lapiscina EH; Lacruz F; Bolado-Concejo F; Rodríguez-Pérez I; Ayuso T; Garaigorta M; Urman JM
    Mult Scler; 2013 Aug; 19(9):1234-5. PubMed ID: 23069876
    [No Abstract]   [Full Text] [Related]  

  • 11. Early onset of natalizumab-related progressive multifocal leukoencephalopathy.
    Damasceno A; von Glehn F; Martinez AR; Longhini AL; Deus-Silva L; Brandão CO; Santos LM; Damasceno BP
    Mult Scler; 2011 Nov; 17(11):1397-8. PubMed ID: 21900356
    [No Abstract]   [Full Text] [Related]  

  • 12. [Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].
    Soilu-Hänninen M; Päivärinta M; Sonninen P; Parkkola R; Vuorinen T; Erälinna JP
    Duodecim; 2013; 129(7):765-70. PubMed ID: 23720945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daclizumab (Zinbryta) for multiple sclerosis.
    Med Lett Drugs Ther; 2016 Sep; 58(1503):117-9. PubMed ID: 27603962
    [No Abstract]   [Full Text] [Related]  

  • 14. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
    N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching from natalizumab to fingolimod: an observational study.
    Sempere AP; Martín-Medina P; Berenguer-Ruiz L; Pérez-Carmona N; Sanchez-Perez R; Polache-Vengud J; Feliu-Rey E
    Acta Neurol Scand; 2013 Aug; 128(2):e6-e10. PubMed ID: 23336398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.
    Kalincik T; Horakova D; Spelman T; Jokubaitis V; Trojano M; Lugaresi A; Izquierdo G; Rozsa C; Grammond P; Alroughani R; Duquette P; Girard M; Pucci E; Lechner-Scott J; Slee M; Fernandez-Bolanos R; Grand'Maison F; Hupperts R; Verheul F; Hodgkinson S; Oreja-Guevara C; Spitaleri D; Barnett M; Terzi M; Bergamaschi R; McCombe P; Sanchez-Menoyo J; Simo M; Csepany T; Rum G; Boz C; Havrdova E; Butzkueven H;
    Ann Neurol; 2015 Mar; 77(3):425-35. PubMed ID: 25546031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision.
    Tur C; Tintoré M; Vidal-Jordana A; Castilló J; Galán I; Río J; Arrambide G; Comabella M; Arévalo MJ; Horno R; Vicente MJ; Caminero A; Nos C; Sastre-Garriga J; Montalban X
    Mult Scler; 2012 Aug; 18(8):1193-6. PubMed ID: 22383232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lethal multiple sclerosis relapse after natalizumab withdrawal.
    Rigau V; Mania A; Béfort P; Carlander B; Jonquet O; Lassmann H; Camu W; Thouvenot E
    Neurology; 2012 Nov; 79(22):2214-6. PubMed ID: 23100404
    [No Abstract]   [Full Text] [Related]  

  • 19. Natalizumab for relapsing-remitting multiple sclerosis.
    Horga A; Tintoré M
    Neurologia; 2011; 26(6):357-68. PubMed ID: 21193250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natalizumab: state of the art and open questions.
    Comi G
    Neurol Sci; 2011 Jan; 31 Suppl 3():313-5. PubMed ID: 21107875
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.